茵栀黄口服液在新生儿病理性黄疸中的应用及对免疫因子与炎症因子的影响  

Application of Yinzhihuang Oral Liquid in Neonatal Pathological Jaundice and Its Influence on Immune Factors and Inflammatory Factors

作　　者：林霞 LIN Xia(Maternal and Child Health Hospital of Fuqing City,Fuqing,Fujian Province,350300 China)

机构地区：[1]福建省福清市妇幼保健院,福建福清350300

出　　处：《中外医疗》2021年第32期191-194,共4页China & Foreign Medical Treatment

摘　　要：目的探讨茵栀黄口服液在新生儿病理性黄疸中的应用及对免疫因子与炎症因子的影响。方法2020年1—12月该院共收治病理性黄疸新生儿484例,将其作为该次研究对象。484例新生儿以随机数表法划分为两组,各242例。对照组采用常规治疗,研究组在此基础上联合茵栀黄口服液治疗。比较两组临床疗效、治疗前后的免疫因子[T淋巴细胞亚群分化簇4(CD4^(+))、分化簇8(CD8^(+))、CD4^(+)/CD8^(+)]与炎症因子[白细胞介素-6(IL-6)、C反应蛋白(CRP)]水平,以及不良反应情况。结果研究组治疗的总有效率97.93%较对照组90.91%高,差异有统计学意义(χ^(2)=11.336,P<0.01)。治疗后研究组CD4^(+)(47.06±5.65)%与CD4^(+)/CD8^(+)(2.08±0.40)较对照组(42.00±5.03)%、(1.68±0.41)高,差异有统计学意义(t=10.406、10.863,P<0.05);CD8^(+)(22.85±2.03)%较对照组(25.68±2.45)%低,差异有统计学意义(t=13.837,P<0.05)。治疗后研究组IL-6(12.62±2.03)pg/mL、CRP(8.20±2.03)mg/L较对照组(19.56±4.00)pg/mL、(15.48±3.52)mg/L低,差异有统计学意义(t=24.068、27.871,P<0.05)。研究组治疗期间不良反应发生率3.31%与对照组2.89%对比,差异无统计学意义(χ^(2)=0.069,P>0.05)。结论茵栀黄口服液在新生儿病理性黄疸中具有显著的应用效果,能够有效调节免疫因子,改善炎症因子,适于临床推广。Objective To explore the application of Yinzhihuang Oral Liquid in neonatal pathological jaundice and its influence on immune factors and inflammatory factors.Methods From January to December 2020,a total of 484 newborns with pathological jaundice were admitted to this hospital,and they were selected as the object of this study.484 newborns were divided into two groups by random number table method,each with 242 cases.The control group received conventional treatment,and the study group was treated with Yinzhihuang Oral Liquid on this basis.To compare the clinical efficacy,immune factors[T lymphocyte subgroup differentiation cluster 4(CD4^(+)),differentiation cluster 8(CD8^(+)),CD4^(+)/CD8^(+)]and inflammatory factors[interleukin-6(IL-6),C-reactive protein(CRP)]levels and adverse reactions.Results The total effective rate of treatment in the study group was 97.93%higher than that in the control group 90.91%,and the difference was statistically significant(χ^(2)=11.336,P<0.05).After treatment,CD4^(+)(47.06±5.65)%and CD4^(+)/CD8^(+)(2.08±0.40)in the study group were higher than those in the control group(42.00±5.03)%and(1.68±0.41).The difference was statistically significant(t=10.406,10.863,P<0.05);CD8^(+)(22.85±2.03)%was lower than the control group(25.68±2.45)%,the difference was statistically significant(t=13.837,P<0.05).After treatment,IL-6(12.62±2.03)pg/mL and CRP(8.20±2.03)mg/L in the study group were lower than those in the control group(19.56±4.00)pg/mL,(15.48±3.52)mg/L,and the difference was statistically significant(t=24.068,27.871,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the study group(3.31%)and the control group(2.89%)during the treatment period(χ^(2)=0.069,P>0.05).Conclusion Yinzhihuang Oral Liquid has a significant application effect in neonatal pathological jaundice.It can effectively regulate immune factors and improve inflammatory factors.It is suitable for clinical promotion.

关 键 词：茵栀黄口服液 新生儿 病理性黄疸 免疫因子 炎症因子 

分 类 号：R5[医药卫生—内科学]